by MM360 Staff | Jul 8, 2020 | Featured News, Myeloma News
The U.S. Food and Drug Administration (FDA) has approved oral XPOVIOTM (selinexor), a nuclear export inhibitor, in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four...
by MM360 Staff | Jun 25, 2020 | Featured News, Myeloma News, Videos
We just added a series of videos with two of the world leading experts in the treatment of myeloma. Dr. Xavier Leleu from the Centre Hospitalier Universitaire de Lille and Dr. Sagar Lonial from Emory University School of Medicine discuss the highlights of new myeloma...
by MM360 Staff | Jul 13, 2018 | EHA 2018, Featured News, Videos
Once-Weekly Vs Twice-Weekly Carfilzomib Dosing Plus Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Results of the Randomized Phase 3 Study A.R.R.O.W. Authors: Maria-Victoria Mateos , Philippe Moreau , James R. Berenson , Katja Weisel ,...
by MM360 Staff | Jul 12, 2018 | EHA 2018, Featured News, Videos
OPTIMISMM: Phase 3 Trial of Pomalidomide, Bortezomib, and Low‐Dose Dexamethasone vs Bortezomib and Low-Dose Dexamethasone in Lenalidomide-Exposed Patients with Relapsed/Refractory Multiple Myeloma Author(s): Paul Richardson , Albert Oriol Rocafiguera , Meral Beksac ,...
by MM360 Staff | Jun 11, 2018 | Featured News, Myeloma News
KYPROLIS, Lenalidomide and Dexamethasone Extended Median Overall Survival in Relapsed or Refractory Multiple Myeloma Patients to 48 Months. The FDA has approved the addition of positive survival data from the ASPIRE Phase 3 clinical trial to the Kyprolis prescribing...
by MM360 Staff Writer | Feb 28, 2018 | Featured News, Myeloma News
A Swedish study published in Haematologica suggests that infections are a major cause of morbidity and mortality in patients with multiple myeloma. The population-based study of 9253 patients showed that infection caused 22% of deaths in patients diagnosed...
